Novel HDL-Raising Drug Appears Safe

ESC 2011 — PARIS — An investigational cholesteryl ester transfer protein (CETP) inhibitor, dalcetrapib, raised HDL cholesterol without any safety concerns in phase IIb dal-VESSEL trial, but it remains to be seen whether that boost in HDL will improve clinical outcomes.

Keywords: ESC Congress


< Back to Listings